<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> protein p53 gene and its negative regulator, murine double minute 2 homolog are important components for cell-cycle arrest and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>An arginine-to-proline substitution at codon 72 in the p53 gene is reported to decrease apoptotic potential, while a <z:chebi fb="2" ids="17821">thymine</z:chebi>-to-<z:chebi fb="1" ids="16235">guanine</z:chebi> polymorphism at nucleotide 309, named SNP309, of murine double minute 2 gene increases transcription of the gene </plain></SENT>
<SENT sid="2" pm="."><plain>These two polymorphisms therefore may be of importance in colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The relation of these polymorphisms to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk was addressed in the Fukuoka <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal Cancer</z:e> Study </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We genotyped the two polymorphisms in 685 incident cases of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and 778 community controls by the polymerase chain reaction-restriction fragment length polymorphism method </plain></SENT>
<SENT sid="5" pm="."><plain>Statistical adjustment was made for sex and age </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The proline allele of p53 gene and the <z:chebi fb="1" ids="16235">guanine</z:chebi> allele of SNP309 were each associated with a small, statistically non-significant increase in the odds ratio of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>; the adjusted odds ratio (95% confidence interval) for arginine/proline and proline/proline genotypes combined versus arginine/arginine genotype of p53 gene was 1.23 (0.99-1.52) and that for <z:chebi fb="2" ids="17821">thymine</z:chebi>/<z:chebi fb="1" ids="16235">guanine</z:chebi> and <z:chebi fb="1" ids="16235">guanine</z:chebi>/<z:chebi fb="1" ids="16235">guanine</z:chebi> genotypes combined versus <z:chebi fb="2" ids="17821">thymine</z:chebi>/<z:chebi fb="2" ids="17821">thymine</z:chebi> genotype of SNP309 was 1.27 (0.98-1.63) </plain></SENT>
<SENT sid="7" pm="."><plain>Individuals harboring the proline allele of p53 gene and the <z:chebi fb="1" ids="16235">guanine</z:chebi> allele of SNP309 showed an odds ratio of 1.67 (95% confidence interval, 1.11-2.51) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Codon 72 polymorphism of p53 and SNP309 in combination may confer an increased risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>